# Development of In Vitro Diagnostics for the Detection of SARS-CoV-2

> **NIH NIH N01** · SORRENTO THERAPEUTICS, INC. · 2023 · $4,590,862

## Abstract

To support the development of promising diagnostics technologies for biothreat pathogens and toxins, as well as pathogens causing emerging and reemerging infectious diseases. Areas of support may focus on improving performance of agnostic nucleic acid sequencing solutions on commercial platforms; methods that improve protein analyte detection; and efforts to improve direct-from-blood or other biofluid detection and identification of microbial infection.

## Key facts

- **NIH application ID:** 10912989
- **Project number:** 75N93023C00024-0-9999-1
- **Recipient organization:** SORRENTO THERAPEUTICS, INC.
- **Principal Investigator:** SCOTT SCHAUS
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $4,590,862
- **Award type:** —
- **Project period:** 2023-06-01 → 2025-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10912989

## Citation

> US National Institutes of Health, RePORTER application 10912989, Development of In Vitro Diagnostics for the Detection of SARS-CoV-2 (75N93023C00024-0-9999-1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10912989. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*